As an additional option, a novel selective ghrelin receptor agonist, anamorelin (ONO-7643), has been approved for patients with cancer cachexia complicated with advanced NSCLC [31] or gastrointestinal cancer [32]. This evidence concerns the gene GHSR and cancer.